SEC Comment Letter for Sorrento Therapeutics, Inc. (SRNE) (CIK 0000850261) — Mar 17, 2020
Sorrento Therapeutics, Inc. (SRNE) (CIK 0000850261)
Date: March 17, 2020 · CIK: 0000850261 · Accession: 0000000000-20-002377
AI Filing Summary & Sentiment
File numbers found in text: 333-237142
Letter
March 17, 2020 Henry Ji, Ph.D. Chief Executive Officer Sorrento Therapeutics, Inc. 4955 Directors Place San Diego, California 92121 Re:Sorrento Therapeutics, Inc. Registration Statement on Form S-3 Filed March 13, 2020 File No. 333-237142 Dear Dr. Ji: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Chris Edwards at (202) 551-6761 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Jeffrey T. Hartlin, Esq.
Show Raw Text
March 17, 2020
Henry Ji, Ph.D.
Chief Executive Officer
Sorrento Therapeutics, Inc.
4955 Directors Place
San Diego, California 92121
Re:Sorrento Therapeutics, Inc.
Registration Statement on Form S-3
Filed March 13, 2020
File No. 333-237142
Dear Dr. Ji:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Chris Edwards at (202) 551-6761 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Jeffrey T. Hartlin, Esq.